NASDAQ
VTGN

VistaGen Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

VistaGen Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.133
Today's High:
$0.1549
Open Price:
$0.1549
52W Low:
$0.08
52W High:
$1.79
Prev. Close:
$0.14
Volume:
10919871

Company Statistics

Market Cap.:
$30.33 million
Book Value:
0.1
Revenue TTM:
$-364000
Operating Margin TTM:
17506.02%
Gross Profit TTM:
$1.11 million
Profit Margin:
0%
Return on Assets TTM:
-66.24%
Return on Equity TTM:
-126.59%

Company Profile

VistaGen Therapeutics Inc had its IPO on 2016-05-06 under the ticker symbol VTGN.

The company operates in the Healthcare sector and Biotechnology industry. VistaGen Therapeutics Inc has a staff strength of 32 employees.

Stock update

Shares of VistaGen Therapeutics Inc opened at $0.15 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.13 - $0.15, and closed at $0.14.

This is a +0.57% increase from the previous day's closing price.

A total volume of 10,919,871 shares were traded at the close of the day’s session.

In the last one week, shares of VistaGen Therapeutics Inc have slipped by -12%.

VistaGen Therapeutics Inc's Key Ratios

VistaGen Therapeutics Inc has a market cap of $30.33 million, indicating a price to book ratio of 0.8384 and a price to sales ratio of 23.1523.

In the last 12-months VistaGen Therapeutics Inc’s revenue was $-364000 with a gross profit of $1.11 million and an EBITDA of $-63587100. The EBITDA ratio measures VistaGen Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, VistaGen Therapeutics Inc’s operating margin was 17506.02% while its return on assets stood at -66.24% with a return of equity of -126.59%.

In Q4, VistaGen Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 49.8%.

VistaGen Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VistaGen Therapeutics Inc’s profitability.

VistaGen Therapeutics Inc stock is trading at a EV to sales ratio of 44.9553 and a EV to EBITDA ratio of 0.1309. Its price to sales ratio in the trailing 12-months stood at 23.1523.

VistaGen Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$29.71 million
Total Liabilities
$4.29 million
Operating Cash Flow
$0
Capital Expenditure
$12500
Dividend Payout Ratio
0%

VistaGen Therapeutics Inc ended 2023 with $29.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $29.71 million while shareholder equity stood at $20.67 million.

VistaGen Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $4.29 million in other current liabilities, 207100.00 in common stock, $-314624700.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.04 million and cash and short-term investments were $25.04 million. The company’s total short-term debt was $891,100 while long-term debt stood at $0.

VistaGen Therapeutics Inc’s total current assets stands at $26.06 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $154100.00 compared to accounts payable of $1.60 million and inventory worth $0.

In 2023, VistaGen Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $12500.

Comparatively, VistaGen Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
$0.14
52-Week High
$1.79
52-Week Low
$0.08
Analyst Target Price
$0.2

VistaGen Therapeutics Inc stock is currently trading at $0.14 per share. It touched a 52-week high of $1.79 and a 52-week low of $1.79. Analysts tracking the stock have a 12-month average target price of $0.2.

Its 50-day moving average was $0.18 and 200-day moving average was $0.26 The short ratio stood at 3.37 indicating a short percent outstanding of 0%.

Around 84.2% of the company’s stock are held by insiders while 1916.9% are held by institutions.

Frequently Asked Questions About VistaGen Therapeutics Inc

The stock symbol (also called stock or share ticker) of VistaGen Therapeutics Inc is VTGN

The IPO of VistaGen Therapeutics Inc took place on 2016-05-06

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
JSR Corp (JSCPY)
$23.71
0.13
+0.55%
Teladoc Inc (TDOC)
$24.43
-0.6
-2.4%
$4.66
-0.14
-2.82%
$116.3
0.98
+0.85%
Dufry AG ADR (DUFRY)
$4.33
0.09
+2.08%
$13.46
-0.01
-0.07%
$95.65
0.65
+0.68%
$0.01
-0
-7.69%
$56.43
0.34
+0.61%
$1.83
0.14
+7.96%

Most Active

Last Price
Chg
Chg%
$0.12
0.02
+20.5%
$0
0
0%
$0
0
0%
$0.59
-0.21
-25.8%

Top Gainers

Last Price
Chg
Chg%
$0
0
+58723.53%
$0
0
+20460.42%
$0.04
0.04
+6566.67%
$0.63
0
+2548.22%
$0.02
0
+1566.67%

Top Losers

Last Price
Chg
Chg%
$0
-0.08
-98.82%
NGC-WT (NGC-WT)
$0
-0.04
-94.66%
$0.11
-0.74
-86.96%
$0.21
-1.03
-83.06%

About

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Address

343 Allerton Avenue, South San Francisco, CA, United States, 94080